NEW YORK-- Goldman Sachs downgraded Johnson& Johnson, saying Tuesday that the current share price has captured all the potential for improved growth. However, Goldman analyst Jami Rubin wrote that Johnson& Johnson comes up short in the two areas she sees as likely to boost stock prices, new prescription drugs and capital allocation.
*Announces FDA 510 clearance and ce mark for Nellcor (TM) bedside. *Says new system will be available in the United States and throughout the eea. in the next few months.
NEW YORK-- Drug and medical device maker Covidien PLC said Tuesday it completed its $100 million purchase of CNS Therapeutics. Covidien announced it was buying CNS on Sept. 24. CNS is now part of Covidien's Mallinckrodt pharmaceuticals business.
Joe Almeida, Covidien president & CEO, discussed his company's strategies for growth and much more.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Every quarter hedge funds and large investors file their holdings with the SEC, revealing value picks, cyclical bets, growth opportunities and activist pushes. TheStreet.com details five stocks that hedge funds flocked to.
Barry Rosenstein, founder of Jana Partners, is best known as an activist investor. The hedge fund manager made intriguing moves in the fourth quarter, buying more shares of Apple and making an outsized bet on Marathon Petroleum.
Cramer makes the call on viewers' favorite stocks.
The “Mad Money” host explains the catalyst behind his call.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Cramer makes the call on viewers' favorite stocks.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!